当前位置: 首页 » 论文全文
←返回首页
期刊信息:
《药学服务与研究》2019年, 第19卷, 第3期, 第210-212页
标题:
吸入型长效抗胆碱能药物及吸入型长效β2受体激动剂在慢性阻塞性肺疾病患者中的应用评价
DOI:
10.5428/pcar20190313
作者:
1. 夏元旦1(1.上海交通大学附属第六人民医院金山分院呼吸科 上海 201599 564569218@qq.com)
2. 2(2.上海市金山区众仁护理医院内科 上海 201501 564569218@qq.com)
3. 杜晓梅1(1.上海交通大学附属第六人民医院金山分院呼吸科 上海 201599 )
4. 周敏1(1.上海交通大学附属第六人民医院金山分院呼吸科 上海 201599 zhoumin-1209@163.com)
5. 沈美珠1(1.上海交通大学附属第六人民医院金山分院呼吸科 上海 201599 )
6. 徐丽1(1.上海交通大学附属第六人民医院金山分院呼吸科 上海 201599 )
7. 唐华1(1.上海交通大学附属第六人民医院金山分院呼吸科 上海 201599 )
摘要:
摘要  目的:探讨吸入型长效抗胆碱能药物(LAMA)及吸入型长效β2受体激动剂(LABA)在稳定期慢性阻塞性肺疾病(COPD)综合评估B、C组患者中的单药应用价值,为COPD个体化治疗提供依据。方法:将91例COPD综合评估B、C组稳定期患者随机分成LAMA组和LABA组,在治疗前及治疗后2、4、6个月记录患者呼吸道症状、COPD评估测试(CAT)评分、第1秒用力呼出量(FEV1)、第1秒用力肺活量占预计值的百分比(FEV1% pred)等,并对两组患者的疗效、肺功能改善及安全性进行评价。结果:在治疗第2、4、6个月,两组患者CAT评分、FEV1值、FEV1% pred均有改善,第6个月与研究起始组内比较差异有统计学意义(P<0.05);在第6个月时LAMA组的FEV1及FEV1% pred均高于LABA组,组间比较差异有统计学意义(P<0.05)。结论:在COPD B、C组稳定期患者的治疗中,LAMA及LABA均可以改善COPD临床症状,在肺功能改善方面LAMA优于LABA。LAMA应用过程中可能引起排尿困难,虽发生率较低但需引起重视。
欢迎阅读《药学服务与研究》!您是该文第 136 位读者!
若需在您的论文中引用此文,请按以下格式著录参考文献:
中文著录格式 夏元旦1,2,杜晓梅1,周敏1,沈美珠1,徐丽1,唐华1. 吸入型长效抗胆碱能药物及吸入型长效β2受体激动剂在慢性阻塞性肺疾病患者中的应用评价[J]. 药学服务与研究. 2019; 19(3): 210-212.
英文著录格式 XIA Yuandan1,2,DU Xiaomei1,ZHOU Min1,SHEN Meizhu1,XU Li1,TANG Hua1. Evaluation of inhaled long-acting anticholinergic drugs and long-acting β2 receptor agonists in the treatment of the patients with chronic obstructive pulmonary disease[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(3): 210-212.
参考文献:
1. Vogelmeier C F,Criner G J,Martinez F J,et al.Global strategy for the diagnosis,management and prevention of chronic obstructive lung disease 2017 report:GOLD executive summary[J].Respirology,2017,22(3):575-601.
2. Guirguis-Blake J M,Senger C A,Webber E M,et al.Screening for chronic obstructive pulmonary disease:evidence report and systematic review for the US preventive services task force[J].JAMA,2016,315(13):1378-1393.
3. Wise R A,Anzueto A,Cotton D,et al.Tiotropium respimat inhaler and the risk of death in COPD[J].N Engl J Med,2013,369(16):1491-1501.
4. Global Initiative for Asthma.2018 GINA Report,Global strategy for asthma management and prevention[EB/OL].[2018-06-30].(2018-10-24).http://ginasthma.org/gina-reports.
5. Latorre M,Novelli F,Vagaggini B,et al.Differences in the efficacy and safety among inhaled corticosteroids(ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD):role of ICS[J].Pulm Pharmacol Ther,2015,30:44-50.
6. Hizawa N.LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes[J].Int J Chron Obstruct Pulmon Dis,2015,10:1093-1102.
7. Singh D,Miravitlles M,Vogelmeier C.Chronic obstructive pulmonary disease individualized therapy:tailored approach to symptom management[J].Adv Ther,2017,34(2):281-299.
8. Chong J,Karner C,Poole P,et al.Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease[J].Cochrane Database Syst Rev,2012,12(9):CD009157.
9. Mahler D A,Kerstjens H A,Donohue J F,et al.Indacaterol vs tiotropium in COPD patients classified as GOLD A and B[J].Respir Med,2015,109(8):1031-1039.
10. ztürk C,Alda Y,Yilmaz Demirci N.Evaluation and importance of different types of inhaler device in patients with chronic obstructive lung disease[J].Tuberk Toraks,2017,65(2):69-79.
11. Yamada H,Hida N,Satoh H,et al.Relationship between lung function and inhalation devices for LAMA/LABA therapy for chronic obstructive pulmonary disease[J].Chron Respir Dis,2018,15(4):419-420.
12. Chrystyn H,Small M,Milligan G,et al.Impact of patients’ satisfaction with their inhalers on treatment compliance and health status in COPD[J].Respir Med,2014,108(2):358-365.
13. Bogart M,Stanford R H,Reinsch T,et al.Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA:a retrospective study[J].Respir Med,2018,142:73-80.
14. Stephenson A,Seitz D,Bell C M,et al.Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease:a population-based study[J].Arch Intern Med,2011,171(10):914-920.